Key Takeaways
- Revenue milestone, margin caution: Quarterly revenue crossed ₹1,000 Cr for the first time, up 11% YoY, but FY26 guidance calls for reported revenue growth of only mid-single digit and a margin reset to the mid-twenties as new biologics facilities come online.
- US biologics acquisition is the strategic bet: The Baltimore facility adds a US foothold and brings total single-use bioreactor capacity to 50KL, but the ramp-up costs will drive the FY26 PAT decline.
- Underlying demand looks healthier than reported numbers: Management expects early-teens underlying revenue growth in FY26, with the gap to reported mid-single digit driven entirely by a client-level inventory balancing in large molecule commercial manufacturing.
- Sequential momentum was real: Revenue and EBITDA margins improved every quarter through FY25, from 21.5% in Q1 to 33.8% in Q4, suggesting the US biotech funding downturn that hurt the first half is easing.
- What to watch next quarter: Whether the inventory destocking in large molecule manufacturing proves a one-quarter event or extends, the pace of cost absorption at the new US and India biologics facilities, and any early signs that FY26 underlying growth is tracking to the early-teens promise.
FY26 Guidance: The Two-Speed Story
- Underlying growth in early teens: Management expects broad-based growth across research, development and manufacturing services, supported by new pilot programs and conversion of existing pilots in discovery services, with mid-term CRDMO sector indicators remaining positive.
- Reported growth at mid-single digit: The gap is entirely attributable to inventory balancing in large molecule commercial manufacturing at the client level, a destocking effect that suppresses reported revenue without reflecting end-demand weakness.
- PAT to decline YoY: The combination of new facility operating costs, higher depreciation, and the inventory adjustment will push profit after tax lower in FY26, with no offsetting tailwinds flagged.
- Margin reset to mid-twenties: EBITDA margin will moderate from the Q4 FY25 level of ~34% as new biologics manufacturing facilities enter operations, adding both operating costs and depreciation.
Deepak Jain: "As we bring the new biologics manufacturing facilities into operations, the additional operating costs and depreciation will impact margins. With this, we expect EBITDA margin to moderate from current levels to the mid-twenties and year-on-year decline in profit after tax."
The US Biologics Bet
- Strategic acquisition closed in Q4: Syngene USA Inc. acquired a state-of-the-art biologics manufacturing facility in Baltimore, Maryland from Emergent Manufacturing Operations Baltimore, LLC, a subsidiary of Emergent BioSolutions Inc., with multiple monoclonal antibody (mAbs) manufacturing lines.
- Capacity now at 50KL: The acquisition increases total single-use bioreactor capacity to 50,000L for large molecule discovery, development, and manufacturing services, providing a strategic foothold in the US market.
- Cost and accounting treatment: Total costs of ₹298.1 Cr (USD 34.89 Mn) accumulated as Capital Work in Progress, with ₹31.1 Cr (USD 3.64 Mn) capitalized as Land, plus pre-transaction costs of ₹10.1 Cr (USD 1.18 Mn), accounted for as an asset acquisition under Ind AS 103.
- The margin drag is front-loaded: The facility will add operating costs and depreciation before it contributes meaningfully to revenue, making it the primary driver of the FY26 margin moderation and PAT decline.
FY25 Full-Year: Resilience in a Divided Year
- Muted first half, recovery in second: FY25 revenue growth of 4.4% to 3,642.4 crore reflected a sectoral downturn in US biotech funding that depressed the first half, followed by a return to growth in the second half, with revenue and EBITDA margins improving sequentially each quarter.
- EBITDA margin held at 28.6%: Full-year operating EBITDA grew 3% with margin down only 48 bps YoY, supported by operational efficiencies and cost optimization programs, despite staff cost pressure of 183 bps and other expense pressure of 133 bps.
- Material costs improved: Material costs as a percentage of revenue improved 79 bps to 25.9%, partially offsetting the staff and other expense headwinds.
- FX swing helped: Net foreign exchange gain of 1.9 crore in FY25 versus a loss of 55.8 crore in FY24 provided a significant tailwind.
- PAT down on one-offs and tax: Reported PAT before exceptional items fell 8% to ₹475 Cr, but adjusted for one-offs including the FY24 Stelis acquisition costs, the FY25 insurance settlement gain, and the Vivad se Vishwas tax settlement, PAT was broadly flat with 1% YoY growth.
- Depreciation benefit from useful life revision: A change in accounting estimate effective April 1, 2024 revised the useful life of manufacturing assets (Plant and Machinery and Equipment), decreasing depreciation expense by ₹20.6 Cr for FY25.
Q4 FY25: The Milestone Quarter
- Revenue crossed ₹1,000 Cr: Quarterly revenue from operations reached 1,018 crore, up 11% YoY and 8% sequentially, the first time the company has crossed the ₹1,000 Cr threshold.
- Broad-based growth: The quarter saw growth across research, development and manufacturing services, with biologics CDMO witnessing robust growth supported by commercial manufacturing alongside new development projects, and high conversion of pilot projects into full programs in discovery services.
- EBITDA up 8% YoY: Operating EBITDA grew to 344.2 crore with margin at 33.8%, down 81 bps YoY but reflecting good underlying fundamentals.
- PAT declined despite revenue growth: Q4 PAT fell 2.8% YoY to 183.3 crore, driven by tax expense jumping 181.1% to 57.2 crore, as Q4 FY24 had benefited from a ₹23.2 Cr tax reversal.
Peter Bains: "Syngene reported revenue growth of 11% year-on-year, and 8% sequentially crossing the Rs. 1,000 Cr in a quarter threshold for the first time. At the EBITDA level growth was 9% year-on-year reflecting good underlying fundamentals. The highlight of the quarter was the acquisition of a state-of-the-art biologics manufacturing facility in the US, strengthening Syngene's position in the fast-growing biologics CDMO sector and providing a strategic foothold in the US market."
Operational Initiatives and Technology
- SYNe-MAP™ ecommerce platform launched: A proprietary B2B platform allowing clients to explore biological assays, configure services, and place orders online, aimed at streamlining the client onboarding and ordering process.
- DMPK automation upgrade: Integration of advanced automation with DMPK operations to enhance speed, consistency and efficiency in drug metabolism and pharmacokinetics services.
- SBTi approval secured: Syngene's emissions reduction targets received approval from the Science Based Targets initiative, adding a sustainability credential relevant to global pharma client procurement requirements.
- Dividend recommended: Board recommended a final dividend of ₹1.25 per share for FY25, subject to shareholder approval.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Underlying revenue growth | Early teens growth, broad-based across research, development and manufacturing | FY26 |
| Reported revenue growth | Mid-single digit, adjusted for client-level inventory balancing in large molecule commercial manufacturing | FY26 |
| EBITDA margin | Moderate to mid-twenties from ~34% in Q4 FY25 | FY26 |
| Profit after tax | Year-on-year decline | FY26 |
| Business momentum | Pipeline build in small and large molecules, supported by new pilot programs and conversion of existing pilots in discovery services | FY26 |
Key Metrics
| Metric | Q4 FY25 |
|---|---|
| Revenue from operations | ₹1,018 Cr, up 11% YoY and 8% QoQ |
| Reported revenue | ₹1,037 Cr, up 11% YoY |
| Operating EBITDA | ₹363 Cr, up 9% YoY |
| Operating EBITDA margin | 35.0%, vs 35.7% in Q4 FY24 |
| Reported PAT (before exceptional items) | ₹183 Cr, down 3% YoY |
| Reported PAT margin | 17.7%, vs 20.2% in Q4 FY24 |
| FY25 revenue from operations | ₹3,642 Cr, up 4% YoY |
| FY25 constant currency revenue growth | 2% |
| FY25 operating EBITDA margin | 29% |
| FY25 PAT before exceptional items | ₹475 Cr, down 8% YoY |
| FY25 PAT after exceptional item | ₹496 Cr, down 3% YoY |
| FY26 revenue growth guidance (underlying) | early teens |
| FY26 reported revenue growth guidance | mid-single digit, adjusted for client inventory balancing in large molecule commercial manufacturing |
| FY26 EBITDA margin guidance | mid-twenties, moderating from current levels due to new biologics facility costs and depreciation |
| Total single-use bioreactor capacity | 50,000L, post US biologics facility acquisition |
| Final dividend per share (FY25) | ₹1.25, recommended, subject to shareholder approval |
| Cash and cash equivalents | 367.1 crore as of 31 March 2025, vs 85.7 crore as of 31 March 2024 |
| Net cash position | improved |